Physician profile
Evan Wayne Hatfill
NPI 1679175996
$17,783.12
in general payments reported to CMS, 2019-2025
27 companies · $3,838 in 2025
The $3,838 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,091 · 2022: $5,820 · 2023: $4,048 · 2024: $2,986 · 2025: $3,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,465.19 |
| Education | $407.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,640.45 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $2,071.89 | 2021-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $2,019.88 | 2021-2025 | |
| Janssen Biotech, INC. | $1,743.78 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $1,320.23 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,292.55 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $937.28 | 2021-2025 | Sotyktu |
| Incyte Corporation | $914.02 | 2021-2024 | Opzelura |
| Genzyme Corporation | $764.58 | 2021-2025 | |
| Leo Pharma INC. | $761.95 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $593.25 | 2023-2025 | Nemluvio, Aklief, Oracea |
| Ucb, INC. | $590.60 | 2023-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $500.79 | 2021-2025 | |
| Amgen INC. | $436.47 | 2021-2025 | Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $314.40 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.60 | 2022-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $178.39 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $129.64 | 2022 | |
| Organon LLC | $113.89 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $106.30 | 2021-2025 | Cabtreo |
| Journey Medical Corporation | $47.18 | 2022-2023 | |
| Fresenius Kabi USA, LLC | $27.31 | 2023 | |
| Biofrontera INC. | $24.34 | 2025 | |
| Epi Health, LLC | $22.76 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.06 | 2025 | Nuzyra |
| Verrica Pharmaceuticals INC. | $15.36 | 2024 | Ycanth |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Hatfill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.